{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD&page=14", "query": { "condition": "PD", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 1540, "total_pages": 154, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PD&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T18:35:57.471Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06644768", "title": "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "valemetostat tosylate", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2024-10-30", "completion_date": "2030-04-30", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06644768" }, { "nct_id": "NCT05878691", "title": "A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "GRC 54276", "type": "DRUG" }, { "name": "GRC 54276 + Pembrolizumab", "type": "DRUG" }, { "name": "GRC 54276 + Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glenmark Specialty S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2022-06-28", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 2, "location_summary": "Huntersville, North Carolina • Milwaukee, Wisconsin", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05878691" }, { "nct_id": "NCT06445972", "title": "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Ramucirumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Tirumotecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" }, { "name": "HER3-DXd", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2024-08-07", "completion_date": "2030-08-08", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445972" }, { "nct_id": "NCT00610194", "title": "Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "RDEA119", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2007-11-28", "completion_date": "2012-08-01", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Buffalo, New York", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00610194" }, { "nct_id": "NCT03815331", "title": "Xiaflex® Plus Testosterone Treatment Pilot Study Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peyronie's Disease (PD)" ], "interventions": [ { "name": "Xiaflex®", "type": "DRUG" }, { "name": "Aveed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Men's Health Boston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "18 Years to 70 Years · Male only" }, "enrollment_count": 20, "start_date": "2019-01-14", "completion_date": "2020-12-30", "has_results": false, "last_update_posted_date": "2020-12-31", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 1, "location_summary": "Chestnut Hill, Massachusetts", "locations": [ { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03815331" }, { "nct_id": "NCT07079631", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "BNT314", "type": "BIOLOGICAL" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "SoC chemotherapy treatment 1", "type": "DRUG" }, { "name": "SoC chemotherapy treatment 2", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 482, "start_date": "2025-07-18", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07079631" }, { "nct_id": "NCT04380142", "title": "Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease (PD)" ], "interventions": [ { "name": "ABBV-951", "type": "DRUG" }, { "name": "Placebo for Levodopa/Carbidopa (LD/CD)", "type": "DRUG" }, { "name": "Levodopa/Carbidopa (LD/CD)", "type": "DRUG" }, { "name": "Placebo for ABBV-951", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 174, "start_date": "2020-10-19", "completion_date": "2021-09-29", "has_results": true, "last_update_posted_date": "2022-11-18", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380142" }, { "nct_id": "NCT02362373", "title": "Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Epilepsy", "Contraception" ], "interventions": [ { "name": "levonorgestrel IUS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 20, "start_date": "2011-08", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2016-01-18", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02362373" }, { "nct_id": "NCT01943851", "title": "A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK525762", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2014-05-14", "completion_date": "2020-04-30", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Aurora, Colorado • New York, New York + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943851" }, { "nct_id": "NCT03033498", "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parkinson's Disease (PD)" ], "interventions": [ { "name": "ABBV-951", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "45 Years to 85 Years" }, "enrollment_count": 29, "start_date": "2017-05-17", "completion_date": "2019-06-08", "has_results": false, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-10-21T18:35:57.471Z", "location_count": 7, "location_summary": "Glendale, California • Orlando, Florida • Grayslake, Illinois + 4 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grayslake", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03033498" } ] }